Moleculin Biotech is trading $0.60, up 5.4%, in pre-market on September 29, following its September 28 announcement of peer-reviewed Annamycin cardiac safety findings. - The pooled analysis, published in Frontiers in Cardiovascular Medicine, covered five clinical trials and 90 patients, revealing no evidence of treatment-related cardiotoxicity. - These positive safety findings, demonstrating Annamycin's ability to overcome cardiotoxicity concerns, are serving as a significant catalyst for the stock's pre-market increase.